Treatment of Spontaneous Hyperventilation With Remifentanil in Traumatic Brain Injury Patients
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Spontaneous hyperventilation is common in severe traumatic brain injury patients and
correlates closely with poor outcomes. How to treat this pathological condition remain
unsolved. Remifentanil is a frequently used short-acting opioid, has the potent side-effect
of dose-dependent respiratory inhibition. Specifically, it prolongs the expiratory time only
and does not influence the respiratory drive. Among the safety range, the investigators will
determine an ideal dose of remifentanil to maintain PaCO2 between 35 to 45 mmHg. The
investigators will monitor the cerebral blood flow of the middle cerebral artery and the
internal carotid artery to validate cerebral perfusion improvement.